Mobile app-maker Vital Art & Science is looking for a pharmaceutical-industry partner after raising $550,000 in support of its MyVisionTrack iPhone vision test.
MASSDEVICE ON CALL — Texas mobile health startup Vital Art & Science is looking for a pharmaceutical industry partner now that it's raised $550,000 in support of its MyVisionTrack iPhone hyperacuity test.
MyVisionTrack is an FDA-cleared smartphone app for detecting age-related macular degeneration and other age-related visual impairments. Vital Art is in the process of seeking approval for the app in the European Union, MobiHealthNews reported.
The company is also looking for some pharmaceutical partners that want to license and market the app, hoping to leverage a larger group to complement its tiny team.
"For a small company to talk directly to doctors and patients is not a feasible thing to do," Vital Art president Mike Bartlett told the news source. "If I work through the drug companies, they've got the big sales staff, they've got reach around the world. If we want to get our test out quickly, to lots of places, we have to work with the big drug companies."
Cook Medical begins a clinical trial of its Evolution esophageal stent.
W.L. Gore & Assoc. appeals its $860 million patent infringement loss to C.R. Bard over stent...
Consultants for Booz Allen Hamilton recommend that the FDA implement more training, metrics and...
Ethicon Endo-Surgery lands 510(k) clearance from the FDA for its Harmonic Focus+ surgical shears.
St. Jude Medical lands CE Mark approval in the European Union for a larger, 25mm version of its...